R. Tonani

发表

Targeted inhibition of the gatekeeper mutant T315I of Bcr-Abl by an Aurora kinase inhibitor

M. Modugno, A. Isacchi, E. Casale, 2007 .

Imidazol-1-yl and pyridin-3-yl derivatives of 4-phenyl-1,4-dihydropyridines combining Ca2+ antagonism and thromboxane A2 synthase inhibition.

P. Cozzi, G. Carganico, M. Menichincheri, 1993, Journal of medicinal chemistry.

Mass spectrometry of some dichloroacetamides of pharmacological interest. Evidence for an unusual skeletal rearrangement

P. Traldi, E. Arlandini, E. Pella, 1986 .

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

Paola Storici, Maurizio Rocchetti, Enrico Pesenti, 2006, Journal of medicinal chemistry.

Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.

A. Vulpetti, F. Roletto, P. Cappella, 2005, Journal of medicinal chemistry.

Mass spectrometry of heterocyclic compounds. VI—retro‐1,3‐dipolar cycloaddition and competitive fragmentation reaction of 2,5‐diaryl‐1,3,4‐dioxazoles

A. Citterio, A. Selva, E. Pella, 1974 .

Enzymatic digestion and mass spectrometry in the study of advanced glycation end products/peptides

Domenico Fedele, Ester Marotta, Roberto Tonani, 2004, Journal of the American Society for Mass Spectrometry.

Structure and molecular orbital study of ergoline derivatives. 1-(6-Methyl-8 beta-ergolinylmethyl)imidazolidine-2,4-dione (I) and 2-(10-methoxy-1,6-dimethyl-8 beta-ergolinyl)ethyl 3,5-dimethyl-1H-2-pyrrolecarboxylate toluene hemisolvate (II) and comparison with nicergoline (III).

R. Fusco, E. Foresti, P. Sabatino, 1988, Acta crystallographica. Section B, Structural science.

The electron impact mass spectrometry of some para substituted trans‐2‐styryl‐6‐carboxychromones. An unusual cleavage of the chromone ring

R. Tonani, 1980 .

The mass spectra of some trans-2-styrl-3-substituted-6-carboxychromones

G. Sollazzo, R. Tonani, 1983 .

Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG

P. Traldi, A. Lapolla, D. Fedele, 2000, Journal of the American Society for Mass Spectrometry.

Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.

D. Volpi, P. Cozzi, A. Giordani, 1994, Journal of medicinal chemistry.

Joint experimental and theoretical investigation of the comparative DNA binding affinities of intercalating anthracycline derivatives.

B. Pullman, N. Gresh, F. Arcamone, 1989, Molecular pharmacology.

Non-enzymatic glycation of IgG: an in vivo study.

A. Lapolla, D. Fedele, D. Favretto, 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

N-imidazolyl derivatives of the napththalene and chroman rings as thromboxane A2 synthase inhibitors

P. Cozzi, D. Severino, G. Carganico, 1991 .

Computer-aided molecular modeling of a D2-agonist dopamine pharmacophore

Garland R. Marshall, James Dunbar, Roberto Tonani, 1987, J. Comput. Aided Mol. Des..